mRNA technology
Coverage of mRNA technology in the Nexus archive.
- Fauci texts suggest officials were ‘too slow to pivot' amid pandemic, says Dr Marc Siegel
Dr. Marc Siegel analyzed newly released text messages from Dr. Anthony Fauci, suggesting that officials were too slow to adapt as scientific understanding of COVID-19 evolved. Siegel criticized Fauci for being 'too dogmatic' and sticking to initial ideas even when evidence changed, particularly regarding issues like vaccination during pregnancy and masking. He noted that the public debate should have shifted alongside changes in vaccine effectiveness and virus mutation, an adjustment he felt Dr. Fauci did not guide fast enough.
- FDA approves Moderna’s mRNA flu vaccine
The U.S. Food and Drug Administration approved Moderna’s mRNA flu vaccine, mFLUSIVA, for adults 50 years and older, issuing an accelerated approval for those 65 and older. The vaccine was found to be about 27% more effective than standard flu shots in a study involving over 40,000 adults. Officials anticipate the shot will be ready in time for the 2026-27 respiratory virus season.
- U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech
The article discusses the U.S. Army's missile stockpiles and the Food and Drug Administration's consideration of a flu vaccine utilizing mRNA technology.
- FDA panel backs first-of-its-kind flu vaccine using mRNA technology
An FDA panel recommended approval of Moderna's first mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older, citing its benefits outweighing risks. The vaccine, developed using technology similar to COVID-19 vaccines, showed a 27% reduction in flu cases compared to traditional vaccines in clinical trials and is under final FDA review for potential approval by August.
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
The FDA is considering Moderna's first mRNA-based flu vaccine, mFlusiva, for people 50 and older. A study showed it reduced flu cases by 27% compared to a standard vaccine, but data on frail older adults and those with weak immune systems is lacking. A prior FDA official disputed the vaccine's comparison to a high-dose brand, but the application was later accepted.
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
The FDA advisory panel is evaluating Moderna's first mRNA-based flu vaccine, mFlusiva, for approval in adults 50 and older. The vaccine, which showed a 27% reduction in flu cases compared to a standard-dose vaccine in a 40,000-person study, faces scrutiny over its study design but has received a favorable FDA review with no safety concerns noted.
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
The FDA is considering Moderna's first mRNA-based flu vaccine, mFlusiva, for adults 50 and older. A study showed it reduced flu cases by 27% compared to a standard vaccine, but lacks data on very frail older adults. The decision follows a dispute with a former FDA official who questioned the study's design.